Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Columbia Laboratories' sale of progesterone related assets to Watson receives stockholder approval

Columbia Laboratories, Inc. announced that in a special meeting of stockholders held this morning, stockholders approved the sale of substantially all of Columbia's progesterone related assets to Watson Pharmaceuticals, Inc.. Stockholders also voted to increase the number of authorized shares of Columbia's common stock, $0.01 par value per share, from 100,000,000 to 150,000,000.

2 Jul 2010

FUISZ files new patent, receives notice of issuance for patent claims for blood analysis devices

First, FUISZ announced that it has received a notice of issuance from the United States Patent and Trademark Office for patent claims that cover a direct connection between prescribing physicians and blood analysis devices.

2 Jul 2010

Lupin's Famotidine for Oral Suspension receives FDA approval

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the US Food and Drug Administration (FDA) for its Famotidine for Oral Suspension (40 mg / 5 mL). Commercial shipments of the product have already commenced.

2 Jul 2010

Studies on VIAject and Vialog presented at 70th American Diabetes Association sessions

Studies of a more-rapid-acting injectable human insulin formulation (VIAject®) in the treatment of type 1 and type 2 diabetes and of a novel insulin analog formulation (Vialog™) in an animal model of diabetes were reported this week in three poster presentations at the 70th Scientific Sessions of the American Diabetes Association in Orlando, Florida. The findings are based upon results from recent clinical and preclinical studies sponsored by Biodel Inc..

1 Jul 2010

pSivida's licensee submits NDA to FDA for Iluvien

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a New Drug Application to the U.S. Food and Drug Administration for Iluvien for Diabetic Macular Edema.

1 Jul 2010

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

BioSante Pharmaceuticals, Inc. announced today positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05).

30 Jun 2010

Novel method of encapsulating gases, liquids and solids using miniature bubbles

Researchers from University College London have won a £25,000 prize for developing technology that could be used to improve medical imaging, the targeted delivery of drugs and much more.

29 Jun 2010

Alimera submits Iluvien NDA for DME to FDA

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Iluvien®, (flucocinolone acetonide intravitreal insert), its investigational, sustained drug delivery system releasing sub-microgram levels of fluocinolone acetonide for the treatment of diabetic macular edema (DME).

29 Jun 2010

AlphaRx regains all rights to Indaflex from Cypress Bioscience

AlphaRx, Inc. today announced that it has entered into an agreement with Cypress Bioscience, under which AlphaRx is regaining all rights to Indaflex(TM) from Cypress Bioscience, which AlphaRx had previously licensed to Proprius Pharmaceuticals, which was subsequently acquired by Cypress Bioscience.

29 Jun 2010

Pluristem advances toward PLX-PAD Phase IIb clinical trials for CLI and Moderate-severe Claudication

Pluristem Therapeutics Inc. today announced that following its meeting with the Paul Ehrlich Institute (PEI), the German regulatory authority for advanced therapy products (ATP), the company is advancing toward designing two Phase IIb clinical trials for its placenta-derived cell therapy product, PLX-PAD, for the treatment of Critical Limb Ischemia (CLI) and Moderate-severe Claudication.

29 Jun 2010

International symposium to highlight current and future applications of MR-guided ultrasound

Leading research and clinical experts from around the world are scheduled to speak at the 2nd International Symposium for MR-guided Focused Ultrasound, which will be held October 17 to 20 in the Washington, D.C. area.

From Elekta 29 Jun 2010

FDA's acceptance for filing of DM-1796 NDA triggers $10M milestone payment to Depomed

Depomed, Inc. today announced that it has received a $10 million milestone payment from Abbott Products, Inc., its licensee of DM-1796, for the U.S. Food and Drug Administration's acceptance for filing of the New Drug Application (NDA) for DM-1796 for the management of postherpetic neuralgia (PHN), or pain after shingles.

29 Jun 2010

Intarcia presents ITCA 650 Phase 2 study results at 70th ADA

Intarcia Therapeutics, Inc. presented today the results of a phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in Orlando, FL (June 25-29, 2010). Results of the phase 2 study demonstrated substantial reductions in HbA1c and body weight during the 12 weeks of treatment with ITCA 650 at both the 20 mcg/day and 40 mcg/day doses.

28 Jun 2010

BioSante joins Russell 3000 Index

BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.

28 Jun 2010

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

Soligenix, Inc., a late-stage biopharmaceutical company, announced today the publication of an article in the June 2010 edition of Vaccine, which describes protection from mucosal and systemic ricin intoxication by intradermal administration of RiVax™, the Company's vaccine against ricin toxin.

28 Jun 2010

Halozyme presents new data from Ultrafast Insulin development program at 70th ADA

Halozyme Therapeutics, Inc. today announced Phase 2 results demonstrating that the subcutaneous coinjection of rHuPH20 (recombinant human hyaluronidase, PH20) with lispro significantly improves postprandial hyperglycemia, reduces hypoglycemia, and accelerates the absorption of mealtime insulin in patients with type 2 diabetes.

28 Jun 2010

Poster presentation at MASCC Conference summarizes MuGard clinical experience

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy.

28 Jun 2010

PecFent receives Positive Opinion from CHMP for treatment of BTCP

Archimedes Pharma, a leading specialty pharma company, today announced that its lead product, PecFent, has received a Positive Opinion from the Committee for Human Medicinal Products, of the European Medicines Agency. The CHMP is recommending PecFent, an innovative fentanyl nasal spray, be authorised for marketing in European Union countries for the treatment of breakthrough cancer pain - sudden, unpredictable episodes of intense pain that occur despite background pain medication.

25 Jun 2010

Quark Pharmaceuticals' siRNA drug candidates featured in two presentations at Glaucoma & Retinopathies 2010

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that two of its siRNA drug candidates were featured in the following two presentations at the Glaucoma & Retinopathies 2010 conference, which was held June 21-22, 2010 in London, UK.

25 Jun 2010

Gene therapy holds promise in treating cancer, cardiovascular and neurodegenerative diseases

EUREKA project E! 3371 Gene Transfer Agents has made great advances in the development of novel non-viral carriers able to introduce genetic material into the target cells.

25 Jun 2010

Drug Delivery News and Research

Further Reading

Columbia Laboratories' sale of progesterone related assets to Watson receives stockholder approval

FUISZ files new patent, receives notice of issuance for patent claims for blood analysis devices

Lupin's Famotidine for Oral Suspension receives FDA approval

Studies on VIAject and Vialog presented at 70th American Diabetes Association sessions

pSivida's licensee submits NDA to FDA for Iluvien

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

Novel method of encapsulating gases, liquids and solids using miniature bubbles

Alimera submits Iluvien NDA for DME to FDA

AlphaRx regains all rights to Indaflex from Cypress Bioscience

Pluristem advances toward PLX-PAD Phase IIb clinical trials for CLI and Moderate-severe Claudication

International symposium to highlight current and future applications of MR-guided ultrasound

FDA's acceptance for filing of DM-1796 NDA triggers $10M milestone payment to Depomed

Intarcia presents ITCA 650 Phase 2 study results at 70th ADA

BioSante joins Russell 3000 Index

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

Halozyme presents new data from Ultrafast Insulin development program at 70th ADA

Poster presentation at MASCC Conference summarizes MuGard clinical experience

PecFent receives Positive Opinion from CHMP for treatment of BTCP

Quark Pharmaceuticals' siRNA drug candidates featured in two presentations at Glaucoma & Retinopathies 2010

Gene therapy holds promise in treating cancer, cardiovascular and neurodegenerative diseases

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News